PE20140923A1 - Preparacion solida que comprende alogliptina y clorhidrato de metformina - Google Patents
Preparacion solida que comprende alogliptina y clorhidrato de metforminaInfo
- Publication number
- PE20140923A1 PE20140923A1 PE2013002763A PE2013002763A PE20140923A1 PE 20140923 A1 PE20140923 A1 PE 20140923A1 PE 2013002763 A PE2013002763 A PE 2013002763A PE 2013002763 A PE2013002763 A PE 2013002763A PE 20140923 A1 PE20140923 A1 PE 20140923A1
- Authority
- PE
- Peru
- Prior art keywords
- solid preparation
- allogliptin
- parts
- metformin hydrochloride
- preparation including
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
REFERIDO A UNA PREPARACION SOLIDA QUE COMPRENDE DOS PARTES: LA PRIMERA PARTE COMPRENDE 2-[[6-[(3R)-3-AMINO-1-PIPERIDINIL]-3,4-DIHIDRO-3-METIL-2,4-DIOXO-1(2H)-PIRIMIDINIL]METIL]BENZONITRILO O UNA DE SUS SALES Y 0-3 PARTES EN PESO DE CLORHIDRATO DE METFORMINA, CON RESPECTO A 100 PARTES EN PESO DEL TOTAL Y LA SEGUNDA PARTE COMPRENDE CLORHIDRATO DE METFORMINA Y 0-0,5 PARTES EN PESO DE 2-[[6-[(3)-3-AMINO-1-PIPERIDINIL]-3,4-DIHIDRO-3-METIL-2,4-DIOXO-1(2H)-PIRIMIDINIL]METIL]BENZONITRILO O UNA DE SUS SALES CON RESPECTO A 100 PARTES EN PESO DEL TOTAL. ADEMAS DICHA PREPARACION COMPRENDE UN ADITIVO TAL COMO CELULOSA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007188574 | 2007-07-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20140923A1 true PE20140923A1 (es) | 2014-08-11 |
Family
ID=39930391
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2013002763A PE20140923A1 (es) | 2007-07-19 | 2008-07-16 | Preparacion solida que comprende alogliptina y clorhidrato de metformina |
PE2008001203A PE20090882A1 (es) | 2007-07-19 | 2008-07-16 | Preparacion solida que comprende alogliptina y clorhidrato de metformina |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2008001203A PE20090882A1 (es) | 2007-07-19 | 2008-07-16 | Preparacion solida que comprende alogliptina y clorhidrato de metformina |
Country Status (27)
Country | Link |
---|---|
US (1) | US8900638B2 (es) |
EP (1) | EP2185138B1 (es) |
JP (2) | JP5479318B2 (es) |
KR (1) | KR101536786B1 (es) |
CN (1) | CN101801351B (es) |
AR (1) | AR067557A1 (es) |
AU (1) | AU2008276842C9 (es) |
BR (1) | BRPI0814299B8 (es) |
CA (1) | CA2694620C (es) |
CO (1) | CO6160301A2 (es) |
CR (1) | CR11267A (es) |
DO (1) | DOP2010000028A (es) |
EA (1) | EA020870B1 (es) |
EC (1) | ECSP109979A (es) |
ES (1) | ES2603879T3 (es) |
GE (1) | GEP20125672B (es) |
IL (1) | IL203171A (es) |
JO (1) | JO3272B1 (es) |
MA (1) | MA31592B1 (es) |
MY (1) | MY159203A (es) |
NZ (1) | NZ583346A (es) |
PE (2) | PE20140923A1 (es) |
TN (1) | TN2010000019A1 (es) |
TW (1) | TWI421102B (es) |
UA (1) | UA98799C2 (es) |
WO (1) | WO2009011451A1 (es) |
ZA (1) | ZA201000831B (es) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
NZ573360A (en) | 2006-05-04 | 2012-08-31 | Boehringer Ingelheim Int | Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
US8900638B2 (en) * | 2007-07-19 | 2014-12-02 | Takeda Pharmaceutical Company Limited | Solid preparation comprising alogliptin and metformin hydrochloride |
JP4989733B2 (ja) * | 2008-02-13 | 2012-08-01 | 大日本住友製薬株式会社 | 口腔内崩壊錠 |
AR071175A1 (es) | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante |
KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
JP5906086B2 (ja) | 2008-08-15 | 2016-04-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Fab関連疾患の治療に用いるためのプリン誘導体 |
JP2012502081A (ja) | 2008-09-10 | 2012-01-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病及び関連症状の治療のための組み合わせ治療 |
AR073380A1 (es) | 2008-09-25 | 2010-11-03 | Takeda Pharmaceutical | Composicion farmaceutica solida. comprimido multicapa |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
TWI508965B (zh) | 2008-12-23 | 2015-11-21 | Boehringer Ingelheim Int | 有機化合物的鹽形式 |
TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
TWI466672B (zh) | 2009-01-29 | 2015-01-01 | Boehringer Ingelheim Int | 小兒科病人糖尿病之治療 |
CN106177958A (zh) | 2009-02-13 | 2016-12-07 | 勃林格殷格翰国际有限公司 | 包含dpp‑4抑制剂(利拉列汀)任选地组合其它抗糖尿病药的抗糖尿病药物 |
CN102361557A (zh) | 2009-03-26 | 2012-02-22 | Mapi医药公司 | 制备阿格列汀的方法 |
WO2010141191A1 (en) * | 2009-05-13 | 2010-12-09 | Wyeth Llc | Method to stabilize a dietary supplement comprising glucosamine |
CA2780939C (en) | 2009-11-13 | 2018-06-12 | Bristol-Myers Squibb Company | Bilayer tablet formulations |
AU2010319377B2 (en) | 2009-11-13 | 2014-10-23 | Astrazeneca Ab | Immediate release tablet formulations |
JP2013512229A (ja) | 2009-11-27 | 2013-04-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 遺伝子型が同定された糖尿病患者のリナグリプチン等のddp−iv阻害薬による治療 |
WO2011113947A1 (en) | 2010-03-18 | 2011-09-22 | Boehringer Ingelheim International Gmbh | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
NZ602921A (en) | 2010-05-05 | 2016-01-29 | Boehringer Ingelheim Int | Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor |
MX2012013069A (es) * | 2010-05-12 | 2013-01-24 | Mapi Pharma Ltd | Polimorfos de benzoato de alogliptina. |
MX2012014247A (es) | 2010-06-24 | 2013-01-18 | Boehringer Ingelheim Int | Terapia para la diabetes. |
JP2012051832A (ja) * | 2010-08-31 | 2012-03-15 | Fancl Corp | 顆粒組成物及びそれを含有する食品又は医薬品 |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
EP3517539B1 (en) | 2011-07-15 | 2022-12-14 | Boehringer Ingelheim International GmbH | Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes |
WO2013077825A1 (en) * | 2011-11-23 | 2013-05-30 | Mahmut Bilgic | Preparation process for a formulation comprising metformin |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
EP2890370B1 (en) | 2012-08-31 | 2019-10-09 | The Regents of the University of California | Agents useful for treating obesity, diabetes and related disorders |
CN103877054B (zh) * | 2012-12-21 | 2016-05-25 | 北大方正集团有限公司 | 一种苯甲酸阿格列汀片剂及其制备方法 |
EP2769712A1 (en) * | 2013-02-21 | 2014-08-27 | Siegfried International AG | Pharmaceutical formulation comprising DPP-IV inhibitor agglomerates and DPP-IV inhibitor particles |
CN103353491B (zh) * | 2013-06-29 | 2018-11-16 | 北京万全德众医药生物技术有限公司 | 一种用液相色谱法分离测定苯甲酸阿格列汀原料及其制剂的方法 |
JP5922310B2 (ja) * | 2013-07-25 | 2016-05-24 | 株式会社三和化学研究所 | 医薬製剤 |
CN104749269B (zh) * | 2013-12-31 | 2018-12-28 | 中美华世通生物医药科技(武汉)有限公司 | 一种利用hplc测定阿格列汀原料药及制剂中对映异构体杂质的方法 |
US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
CN105527348B (zh) * | 2014-09-28 | 2018-07-24 | 中美华世通生物医药科技(武汉)有限公司 | 分离分析苯甲酸阿格列汀制剂及其有关物质的方法 |
CN104569172A (zh) * | 2014-11-05 | 2015-04-29 | 广东东阳光药业有限公司 | 一种用液相色谱检测苯甲酸阿格列汀片溶出度的方法 |
CN105675733B (zh) * | 2014-11-17 | 2020-01-31 | 重庆医药工业研究院有限责任公司 | 一种用液相色谱法分离测定琥珀酸曲格列汀及其光学异构体的方法 |
MY180521A (en) * | 2014-12-03 | 2020-12-01 | Caffitaly System Spa | Containment body for making a capsule for making beverages and method for making capsules with different quantities of powdered food substance using a single type of containment body |
CN107810005B (zh) | 2015-06-17 | 2021-04-20 | 赫克萨尔股份公司 | 阿格列汀制剂 |
WO2017029609A1 (en) * | 2015-08-20 | 2017-02-23 | Torrent Pharmaceuticals Limited | Pharmaceutical composition of alogliptin and metformin |
US20180235911A1 (en) * | 2015-08-21 | 2018-08-23 | Alembic Pharmaceuticals Limited | Stable pharmaceutical composition of alogliptin and metformin fixed dose combination |
AU2016343851B2 (en) * | 2015-10-30 | 2022-04-07 | Cancer Prevention Pharmaceuticals, Inc. | Eflornithine and sulindac, fixed dose combination formulation |
EP3468562A1 (en) | 2016-06-10 | 2019-04-17 | Boehringer Ingelheim International GmbH | Combinations of linagliptin and metformin |
CN106008277A (zh) * | 2016-06-12 | 2016-10-12 | 聊城大学 | 一种新型二甲双胍盐酸盐及其制备方法 |
CN106421794A (zh) * | 2016-09-27 | 2017-02-22 | 黑龙江珍宝岛药业股份有限公司 | 一种用于治疗ⅱ型糖尿病的药物组合物及其制备方法 |
CN108318610A (zh) * | 2017-12-29 | 2018-07-24 | 合肥拓锐生物科技有限公司 | 一种苯甲酸阿格列汀原料及其制剂中有关物质的分析方法 |
EP3784672A4 (en) | 2018-04-27 | 2022-03-30 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | TABLET FORMULATIONS INCLUDING METFORMIN AND SITAGLIPTIN |
CN108743611A (zh) * | 2018-06-20 | 2018-11-06 | 常州制药厂有限公司 | 一种复方利血平片的制备方法 |
WO2020098904A1 (en) | 2018-11-12 | 2020-05-22 | Pharmaceutical Oriented Services Ltd | Dosage form containing metformin and a dipeptidyl peptidase iv inhibitor |
TR201907905A1 (tr) * | 2019-05-24 | 2020-12-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Alogli̇pti̇n ve metformi̇n i̇çeren bi̇r kombi̇nasyon |
CN111537622B (zh) * | 2019-11-29 | 2021-11-26 | 杭州华东医药集团新药研究院有限公司 | 一种度格列汀及其盐的杂质的检测方法 |
KR20230051096A (ko) | 2021-10-08 | 2023-04-17 | (주)셀트리온 | 안정성이 개선된 당뇨병 치료용 약학 조성물 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3174901A (en) | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
JPS49110814A (es) * | 1973-03-02 | 1974-10-22 | ||
CN1072649C (zh) | 1995-09-13 | 2001-10-10 | 武田药品工业株式会社 | 苯并氧杂吖庚因化合物,其生产方法和用途 |
EP1052994A2 (en) | 1998-02-02 | 2000-11-22 | Trustees Of Tufts College | Use of dipeptidylpetidase inhibitors to regulate glucose metabolism |
PT974356E (pt) | 1998-07-15 | 2004-02-27 | Merck Sante Sas | Comprimidos compreendendo uma combinacao de metformina e de glibenclamida |
AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
US6559188B1 (en) | 1999-09-17 | 2003-05-06 | Novartis Ag | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
ITMI20002019A1 (it) | 1999-09-17 | 2002-03-15 | Novartis Ag | Metodo per il trattemento dei disturbi metabolici, in particolare diabete oppure una malattia oppure una condizione associate con il diabete |
BR0015294A (pt) | 1999-11-03 | 2003-07-15 | Bristol Myers Squibb Co | Método para tratamento da diabetes |
CA2407149C (en) | 2000-04-28 | 2010-10-12 | Takeda Chemical Industries, Ltd. | Melanin-concentrating hormone antagonist |
US6780432B1 (en) | 2000-05-01 | 2004-08-24 | Aeropharm Technology, Inc. | Core formulation |
US6403121B1 (en) | 2000-05-01 | 2002-06-11 | Aeropharm Technology Incorporated | Core formulation |
AU2001256733A1 (en) | 2000-05-16 | 2001-11-26 | Takeda Chemical Industries Ltd. | Melanin-concentrating hormone antagonist |
GB0014969D0 (en) | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
AU2002257582A1 (en) * | 2001-02-14 | 2002-09-04 | Glaxo Wellcome S.A. | Pharmaceutical formulation |
US6524618B1 (en) * | 2001-06-12 | 2003-02-25 | Vijai Kumar | Directly compressible extended-release matrix formulation for metformin hydrochloride |
ATE386523T1 (de) | 2001-07-17 | 2008-03-15 | N Gene Res Lab Inc | Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes |
JP2005508331A (ja) | 2001-09-28 | 2005-03-31 | サン・ファーマシューティカル・インダストリーズ・リミテッド | 糖尿病の処置のための投与製剤 |
US20030187074A1 (en) | 2002-03-04 | 2003-10-02 | Javed Hussain | Oral compositions for treatment of diabetes |
US20030224046A1 (en) * | 2002-06-03 | 2003-12-04 | Vinay Rao | Unit-dose combination composition for the simultaneous delivery of a short-acting and a long-acting oral hypoglycemic agent |
US20040125143A1 (en) | 2002-07-22 | 2004-07-01 | Kenneth Deaton | Display system and method for displaying a multi-dimensional file visualizer and chooser |
ATE461212T1 (de) | 2002-09-18 | 2010-04-15 | Prosidion Ltd | Sekundäre bindungsstelle von dipeptidylpeptidase iv (dp iv) |
JPWO2004028524A1 (ja) | 2002-09-26 | 2006-01-19 | エーザイ株式会社 | 併用医薬 |
UA80991C2 (en) | 2002-10-07 | 2007-11-26 | Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes | |
US20070099884A1 (en) | 2003-06-06 | 2007-05-03 | Erondu Ngozi E | Combination therapy for the treatment of diabetes |
DE602004010206T2 (de) | 2003-08-13 | 2008-10-09 | Takeda Pharmaceutical Co. Ltd. | Dipeptidyl Peptidase Inhibitoren. |
US7442720B2 (en) | 2003-12-19 | 2008-10-28 | Omega Bio-Pharma (I.P.3) Limited | Compositions and methods for treating diabetes |
CA2559302C (en) | 2004-03-15 | 2012-06-19 | Takeda Pharmaceutical Company Limited | 6-amino-1h-pyrimidine-2,4-dione derivatives as dipeptidyl peptidase inhibitors |
KR100760430B1 (ko) | 2004-12-31 | 2007-10-04 | 한미약품 주식회사 | 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법 |
MXPA05009633A (es) * | 2005-09-08 | 2007-03-07 | Silanes Sa De Cv Lab | Composicion farmaceutica estable de glimepirida de liberacion inmediata y metformina de liberacion prolongada. |
WO2007033266A2 (en) * | 2005-09-14 | 2007-03-22 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors for treating diabetis |
TW200745079A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor |
CN101365432B (zh) | 2005-12-16 | 2011-06-22 | 默沙东公司 | 二肽基肽酶-4抑制剂与二甲双胍的组合的药物组合物 |
GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
MEP7609A (en) * | 2005-12-28 | 2011-12-20 | Therapeutic agent for diabetes | |
RU2333760C2 (ru) | 2006-05-16 | 2008-09-20 | Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") | Твердая дозированная лекарственная форма для лечения сахарного диабета |
TW200826936A (en) * | 2006-12-01 | 2008-07-01 | Merck Frosst Canada Ltd | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
BRPI0807453B8 (pt) * | 2007-02-01 | 2021-05-25 | Takeda Pharmaceuticals Co | preparação sólida |
EP2124901B1 (en) | 2007-02-01 | 2017-07-19 | Takeda Pharmaceutical Company Limited | Tablet preparation without causing a tableting trouble |
US8900638B2 (en) * | 2007-07-19 | 2014-12-02 | Takeda Pharmaceutical Company Limited | Solid preparation comprising alogliptin and metformin hydrochloride |
RU2380097C1 (ru) | 2009-01-20 | 2010-01-27 | Общество с ограниченной ответственностью "ИТЭРА" | Твердая дозированная лекарственная форма для лечения сахарного диабета |
-
2008
- 2008-07-16 US US12/452,705 patent/US8900638B2/en active Active
- 2008-07-16 TW TW097126889A patent/TWI421102B/zh active
- 2008-07-16 CN CN2008801080345A patent/CN101801351B/zh active Active
- 2008-07-16 CA CA2694620A patent/CA2694620C/en active Active
- 2008-07-16 WO PCT/JP2008/063228 patent/WO2009011451A1/en active Application Filing
- 2008-07-16 KR KR1020107003605A patent/KR101536786B1/ko active IP Right Grant
- 2008-07-16 MY MYPI2010000240A patent/MY159203A/en unknown
- 2008-07-16 BR BRPI0814299A patent/BRPI0814299B8/pt active IP Right Grant
- 2008-07-16 NZ NZ583346A patent/NZ583346A/en unknown
- 2008-07-16 PE PE2013002763A patent/PE20140923A1/es active IP Right Grant
- 2008-07-16 AU AU2008276842A patent/AU2008276842C9/en active Active
- 2008-07-16 AR ARP080103045A patent/AR067557A1/es not_active Application Discontinuation
- 2008-07-16 UA UAA201001761A patent/UA98799C2/ru unknown
- 2008-07-16 GE GEAP200811694A patent/GEP20125672B/en unknown
- 2008-07-16 EP EP08791480.0A patent/EP2185138B1/en active Active
- 2008-07-16 JP JP2010502373A patent/JP5479318B2/ja active Active
- 2008-07-16 PE PE2008001203A patent/PE20090882A1/es active IP Right Grant
- 2008-07-16 JO JOP/2008/0322A patent/JO3272B1/ar active
- 2008-07-16 EA EA201070164A patent/EA020870B1/ru unknown
- 2008-07-16 ES ES08791480.0T patent/ES2603879T3/es active Active
-
2010
- 2010-01-06 IL IL203171A patent/IL203171A/en active IP Right Grant
- 2010-01-11 TN TNP2010000019A patent/TN2010000019A1/fr unknown
- 2010-01-19 DO DO2010000028A patent/DOP2010000028A/es unknown
- 2010-02-04 ZA ZA2010/00831A patent/ZA201000831B/en unknown
- 2010-02-05 MA MA32588A patent/MA31592B1/fr unknown
- 2010-02-12 CR CR11267A patent/CR11267A/es unknown
- 2010-02-19 CO CO10019969A patent/CO6160301A2/es unknown
- 2010-02-19 EC EC2010009979A patent/ECSP109979A/es unknown
-
2013
- 2013-11-26 JP JP2013243967A patent/JP2014058547A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20140923A1 (es) | Preparacion solida que comprende alogliptina y clorhidrato de metformina | |
UY30600A1 (es) | Compuestos novedosos | |
CO6311101A2 (es) | Esteres y tioesteres del acido tiazol -4-carboxilico como agentes fitoprotectores | |
DOP2010000047A (es) | Compuestos de pirazol y su uso como inhibidores de raf | |
EA201100580A1 (ru) | Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы | |
SV2009003376A (es) | Derivados de aril isoxazolinas insecticidas | |
HN2010001274A (es) | Compuestos insecticidas | |
DOP2011000165A (es) | Compuesto heterociclico y uso del mismo | |
CR11512A (es) | Compuestos insecticidas | |
ME01239B (me) | Čvrsti preparat koji sadrži alogliptin i pioglitazon | |
AR065698A1 (es) | Preparacion solida | |
CR10662A (es) | Compuestos de metilpiridopirimidinona | |
AR065280A1 (es) | Agentes antiparasitarios | |
CO6390028A2 (es) | Amidas del ácido antranílico sustituidas con tetrazol como plaguicidas | |
EA200800727A1 (ru) | Введение ингибиторов дипептидилпептидазы | |
PA8649401A1 (es) | Analogos de anilino-pirimidina | |
UY32366A (es) | Compuestos de amidina sustituida para combatir plagas de animales | |
AR055613A1 (es) | Formas cristalinas delta y epsilon de mesilato de imatinib | |
BRPI0918472A2 (pt) | composto 2,4-diaminopirimidina | |
DK2074120T3 (da) | Tropan-forbindelser | |
ECSP099565A (es) | Compuesto de 2-amino pirimidina | |
GT200600063A (es) | Tetraciclinas 9-sustituidas | |
UY31688A1 (es) | Plaguicidas | |
CL2012000182A1 (es) | Tableta que comprende 2-[[6-[(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)pirimidinil]metil]-4-fluorobenzonitrilo en un 35 a 50% en peso y un fluidizador; y método para producirla. | |
SV2011003857A (es) | Sales n-[6-(cis-2,6-dimetil-morfolin-4-il)- piridin-3-il]-2-metil-4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |